Medicinal Cannabis

The TGA medicinal cannabis landscape has evolved since its legalisation in 2016, and it continues to evolve, and many organisation are being caught for non-compliance with TGA standards including advertising.

With experience across prescription cannabis medicines, consumer cannabis medicines and and TGO93, the Enimera RegsPlus team can drive and support your organisation’s medicinal cannabis projects.

Whether your organisation seeks regulatory resource for a medicinal cannabis product strategy or application, or ad-hoc TGO93-related or SAS/Authorised Prescriber advice, contact Enimera RegsPlus to understand how we can support you.

For more on medicinal cannabis regulation and TGA GMP requirements, click here.

Adverse Events Trends Analysis

Tailored for organisations supplying medicinal cannabis in Australia via the Special Access Scheme or Authorised Prescriber Pathway, our AETA model provides you with templates and reports to allow you to better understand your products and enhance your regulatory compliance.

Contact us for a confidential discussion of your needs.

Proudly a member of

Get in touch to find out how Enimera RegPlus can help you